{"id":"W2947752713","doi":"10.1200/jco.2019.37.15_suppl.5003","title":"Updated results from a randomized phase II study of cabazitaxel (CAB) versus abiraterone (ABI) or enzalutamide (ENZ) in poor prognosis metastatic CRPC.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Prevention of Organ Failure; Princess Margaret Cancer Centre; Baker Hughes (Canada); University of Alberta; Dalhousie University; Regional Municipality of Durham; Lakeridge Health; Juravinski Cancer Centre; University of Manitoba; Saskatchewan Cancer Agency; Ottawa Hospital; BC Cancer Agency; Jewish General Hospital; University of British Columbia","funders":"","keywords":"Medicine; Enzalutamide; Internal medicine; Cabazitaxel; Docetaxel; Progression-free survival; Oncology; Abiraterone acetate; Prostate cancer; Randomized controlled trial; Abiraterone; Androgen receptor; Gastroenterology; Urology; Androgen deprivation therapy; Overall survival; Chemotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003172647,0.0009606841,0.001978402,0.0003309806,0.0002467713,0.0008850831,0.000788421,0.0009802702,0.008206658],"category_scores_gemma":[0.003599481,0.0004592295,0.001968252,0.0005387333,0.0003990744,0.0006420626,0.0002636274,0.002289767,0.000995112],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007413692,"about_ca_system_score_gemma":0.001148945,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001648777,"about_ca_topic_score_gemma":0.005829577,"domain_scores_codex":[0.9990795,0.0005584413,0.00007538073,0.00008982358,0.0001013683,0.00009554078],"domain_scores_gemma":[0.9969201,0.001113595,0.000949603,0.0001820022,0.0002089264,0.0006258663],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.92763,0.00383982,0.003474464,0.001221852,0.00291147,0.00008932378,0.00008371778,0.0009008538,0.005802192,0.00009716916,0.005508391,0.04844064],"study_design_scores_gemma":[0.9004344,0.06874304,0.01992518,0.0001565684,0.004639142,0.0001592984,0.00003784848,0.0004482265,0.0008853434,0.0002423632,0.004301085,0.00002752407],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.942106,0.02473859,0.001683395,0.002433879,0.0009883996,0.004989673,0.01667458,0.0002174991,0.006167943],"genre_scores_gemma":[0.9602604,0.009556271,0.002955904,0.003110908,0.0005098384,0.003619202,0.01562527,0.0000657344,0.004296471],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008206658,"threshold_uncertainty_score":0.02745402,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09457267435545368,"score_gpt":0.4400768584416765,"score_spread":0.3455041840862228,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}